BioMedNewsBreaks Archive - Page 3 of 248

MondayDec 22, 2025 9:46 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform

Oncotelic Therapeutics (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to extract biologically meaningful signals from large and complex biomedical datasets without training bespoke large language models on proprietary data. The company is also providing researchers access to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel, with the platform developed alongside Oncotelics clinical and preclinical programs to enhance the speed, depth, and efficiency of discovery across its pipeline. To view the full press release, visit https://ibn.fm/U31jX About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the…

FridayDec 19, 2025 9:33 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

Nutriband (NASDAQ: NTRB) announced the signing of a nonbinding letter of intent with the Qvanta Group of Companies to explore potential collaboration involving secure artificial intelligence, advanced computing, and cybersecurity technologies that may support Nutriband’s research and long-term product development initiatives. The company said the discussions will focus on areas such as secure AI and analytics platforms for regulated pharmaceutical data, data integrity frameworks supporting abuse-deterrent technologies, and advanced modeling and simulation enabled by quantum-ready infrastructure, while emphasizing that the LOI does not establish a partnership or commercial relationship and that any future collaboration would be subject to further review, due diligence, and definitive agreements. To…

ThursdayDec 18, 2025 11:07 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease

Soligenix (NASDAQ: SNGX) announced that results from its Phase 2a proof-of-concept study evaluating SGX945 (dusquetide) for the treatment of aphthous ulcers associated with Behçet’s Disease have been published in Rheumatology (Oxford), reporting beneficial effects in seven of eight patients with sustained improvement through a four-week follow-up period after treatment ended. The company said outcomes for SGX945, including reductions in oral ulcers and pain and favorable area under the curve measurements, were comparable to those reported in a Phase 3 study of apremilast (Otezla(R)), despite SGX945 dosing stopping at Week 4 while apremilast required continuous administration. Soligenix noted SGX945 was well tolerated with no treatment-related adverse events observed and said it…

ThursdayDec 18, 2025 10:58 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

Nutriband (NASDAQ: NTRB) said the Trump Administration Executive Order designating illicit fentanyl and its core precursor chemicals as weapons of mass destruction should not be conflated with “FDA”-approved prescription fentanyl therapies such as transdermal fentanyl patches, which it said are produced under rigorous regulatory oversight and remain medically necessary for certain severe chronic pain patients. The White House+1 The company noted ongoing concerns around transdermal fentanyl patch abuse and accidental pediatric exposure and said it is partnering with Kindeva to develop AVERSA(TM) FENTANYL, which combines Nutriband AVERSA(TM) abuse-deterrent technology with Kindeva FDA-approved fentanyl patch to deter abuse and reduce accidental exposure while maintaining access for patients who need prescription fentanyl products. Nutriband said AVERSA(TM)…

ThursdayDec 18, 2025 9:15 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has repaid the remaining $5.4 million of balance sheet debt owed to Anson Funds LLC through an equity conversion into common stock with no warrants or repricing mechanisms, fully retiring the original $16.2 million loan used for prior debt repayment and operating expenses. With the transaction completed, the clinical-stage biopharmaceutical company expects to end calendar year 2025 debt free, positioning its capital structure to support anticipated drug approvals and clinic expansions, with Chairman and CEO Dr. Jonathan Javitt thanking Anson for its support during a challenging biotech market and citing progress toward potential 2026…

WednesdayDec 17, 2025 2:00 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest’s “Total Cardiac Intelligence” report. “The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. The recognition highlights HeartBeam’s growing influence in the next generation of cardiac monitoring technology,” reads the article. “HeartBeam’s ranking underscores the rapid maturation of the company’s proprietary synthesis-ECG system, which captures the heart’s electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique…

WednesdayDec 17, 2025 12:25 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for primary and metastatic cancers of the brain and central nervous system, reported a leadership transition under which John Climaco has stepped down as chief executive officer and Rami Levin, MBA, has been appointed president and chief executive officer, effective Jan. 1, 2026. Levin brings nearly three decades of global leadership experience across oncology, neurology and rare diseases, with a track record of advancing late-stage clinical programs, scaling organizations and leading strategic turnarounds, positioning CNS to advance its pipeline and next phase of development. To view the full press release, visit https://ibn.fm/WY7pj About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a…

WednesdayDec 17, 2025 9:20 am

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases with unmet medical need, reported extended results from its ongoing Phase 2a trial evaluating SGX302 (synthetic hypericin) for mild-to-moderate psoriasis, including outcomes from an additional cohort treated with an optimized topical gel formulation. The gel was well tolerated with no drug-related adverse events and demonstrated improvements across multiple clinical and quality-of-life measures, including Investigator Global Assessment and Psoriasis Area and Severity Index scores, with results comparable to or exceeding those observed with the prior ointment formulation, supporting continued development of SGX302 as a potential non-carcinogenic, non-mutagenic therapeutic…

MondayDec 15, 2025 11:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences

Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter,” which analyzes the prognostic significance of biomarkers DNMT3A and GMPS across hepatocellular carcinoma and pancreatic ductal adenocarcinoma. Drawing on survival, transcriptomic, and tumor microenvironment data from more than 7,000 patients, the study demonstrates that biomarker relevance is highly context-dependent, shaped by immune composition, metabolic reprogramming, and innate immune signaling pathways, while also highlighting the role of structured mentorship in advancing translational oncology…

ThursdayDec 11, 2025 11:33 am

BioMedNewsBreaks — Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced the preprint release of research introducing Capture-Seq(TM), a new method for analyzing transcription factor–protected ultrashort DNA fragments in blood as potential low-cost cancer biomarkers. The manuscript, titled “Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq,” highlights Volition’s achievement of 180-fold enrichment of transcription factor–bound fragments by focusing on DNA in its natural chromosomal context rather than on chemically extracted DNA, overcoming the longstanding challenge of overwhelming background DNA in liquid biopsy testing. Early findings from a 70-person training cohort showed 100 percent sensitivity and 100 percent…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Signs LOI to Explore Quantum-AI Technology Collaboration

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Positive Phase 2a SGX945 Data in Behçet’s Disease

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Responds to Fentanyl WMD Executive Order, Highlights AVERSA(TM) FENTANYL Development

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Ranks Second Worldwide in 12-Lead ECG Innovation

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Rami Levin as President and Chief Executive Officer

BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Reports Extended Phase 2a Results for SGX302 Gel in Mild-to-Moderate Psoriasis

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences

BioMedNewsBreaks — Volition Solves Liquid Biopsy’s “Needle in a Haystack” Problem; Achieves 180-fold (18,000%) Enrichment

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search